Total: $1,063.07M | ||||
Company |
Type Of Financing | Number Of |
Amount |
Investors; Placement Agents; Details (Date)@ |
| | ||||
Abgenix Inc. |
Private placement of convertible notes |
N/A |
$225 |
The 1.75% senior notes due in 2011 are convertible into common stock at $12.82 per share; purchasers have an option to buy another $75M of the notes (12/15) |
Aradigm |
Private placement of stock and warrants |
8.3S and ND |
$12.5 |
The shares were sold at $8.50 each, a discount of 16%; warrant details were not disclosed; SG Cowen was lead placement agent and Punk, Ziegel was co-agent for the deal (12/20) |
Biomira Inc. |
Private placement of stock and warrants |
4.89S and 0.978W |
$12.57 |
The shares were sold from a shelf registration at $2.57 each, a 15% discount; the three- year warrants are exercisable at $3.45 per share; Rodman & Renshaw LLC was placement agent (12/9) |
Biopure Corp. |
Private placement of stock and warrants |
40S and 20W |
$11.6 |
The company sold 40M shares at $0.29 each and 20M warrants exercisable at $0.31 per share from a shelf registration to institutional and individual investors; C.E. Unterberg, Towbin LLC was placement agent (12/9) |
Bio-Rad |
Private placement of notes |
N/A |
$200 |
The 6.125% senior subordinated notes are due in 2014 (12/13) |
Cell |
Private placement of stock |
2.586S |
$18.5 |
The shares from a shelf registration were sold to institutional investors in a direct offering at $7.10 each (12/20) |
Cortex |
Private placement of stock and warrants |
4.233S and 2.117W |
$11.26 |
New and existing institutional investors purchased the shares at $2.66 each; the five-year warrants are exercisable at $3 per share; Rodman & Renshaw LLC was placement agent (12/15) |
DOV |
Private placement of convertible notes |
N/A |
$65 |
The convertible subordinated debentures due 2025 have an interest rate of 2.5%; the initial conversion price is $22.75 per share; investors have an option to purchase another $15M in notes (12/16) |
Emisphere Inc. (EMIS) |
Private placement of stock |
N/A |
$20 |
Kingsbridge Capital Ltd. committed to purchase up to $20M of Emisphere stock over two years; Emiisphere can sell shares equal to 3% of its market cap at discounts of 8% to 12%; Kingsbridge got a warrant to purchase 250,000 shares at a premium as part of the deal (12/28) |
EntreMed |
Private placement of stock and warrants |
5.5S and 1.1W |
$14 |
The shares were sold at $2.55 each; the five-year warrants are convertible at a 15% premium; Rodman & Renshaw LLC was placement agent; Ferghana Partners also participated (12/27) |
Genitope |
Private placement of stock |
4.25S |
$60.6 |
The shares were sold at $14.25 each in a private placement with institutional and accredited investors; WR Hambrecht + Co. LLC was placement agent (12/14) |
Genta Inc. |
Private placement of stock |
15S |
$22.5 |
Genta agreed to sell two institutional investors the shares at $1.50 each, from a shelf registration; Rodman & Renshaw LLC was placement agent (12/15) |
Halozyme |
Warrants exercise |
1.57S |
$2.75 |
Holders of warrants exercised them for the purchase of about 1.57M shares (12/15) |
ID Biomedical |
Loan |
N/A |
$60 |
Second City Capital Partners provided the 8% loan that becomes due in 18 months; it also received two-year warrants to purchase 1.2M common shares at $16.91 per share (12/22) |
Innovative |
Private placement of stock |
6S |
$18 |
The shares were sold at $3 each in conjunction with privately held IDDS' merger with Intrac Inc., under which IDDS was the surviving entity; Rodman & Renshaw was placement agent (12/7) |
Introgen |
Private placement of stock |
0.975S |
$7.8 |
The shares were sold from a shelf registration to the same European investors that participated in a financing two days earlier; Mulier Capital was placement agent (12/10) |
Introgen |
Private placement of stock |
2.47S |
$16.4 |
The shares were sold from a shelf registration; more than $15M of the total was placed with two European institutional investors; Mulier Capital was placement agent (12/8) |
Lynx |
Bridge loan |
N/A |
$3 |
Silicon Valley Bank provided the facility, backed by Lynx's assets (12/30) |
Millenium |
Private placement of stock |
5.45S |
C$15 (US$12.4) |
The shares were sold at C$2.75 each, a deal done in conjunction with its acquisistion of Cytovax Biotechnologies Inc.; RBC Capital Markets was lead agent in the financing, with Dlouhy Merchant Group Inc. as co-agent (12/3) |
Mologen AG (Germany; FSE:MGNG) |
Private placement of stock |
0.55S |
€1.16 |
Mologen issued the shares at €2.10 each against cash deposits of institutional investors (12/20) |
Neoprobe |
Private placement of notes and warrants |
N/A |
$8.1 |
Great Point Partners LLC purchased $8M of the four-year, 8% notes that are convertible into stock at $0.40 per share; the warrants are exercisable for 10.125M shares at $0.46 per share (12/14) |
NexMed |
Private |
5.495S and 2.75W |
$7.03 |
The shares were sold at $1.28 each; five-year warrants to purchase 2.198M shares are exercisable at $1.47 per share; one-year warrants to purchase 549,536 shares are exercisable at $2 per share (12/22) |
NPS |
Private placement of notes |
N/A |
$175 |
The 8% notes were placed with institutional investors and are secured by revenues paid to NPS from sales of Sensipar, a drug licensed to and sold by Amgen Inc. (12/23) |
Oncolytics |
Warrants exercise |
1.265S |
$5.06 |
Investors in a June 2003 financing exercised warrants for about 1.265M shares (12/21) |
OXIS |
Private placement of stock and warrants |
12.26S and 12.26W |
$6.5 |
The shares were sold at $0.53 each; half the warrants are exercisable at $0.66 per share and half at $1 per share; Rodman & Renshaw LLC was placement agent (12/31) |
Penwest |
Private placement of stock |
3.125S |
$35 |
The shares were sold to institutional and other investors at $11.20 each (12/10) |
Peplin Ltd. |
Rights issue |
24.3S |
A$10.2 |
Shareholders purchased about 75% of the shares in the rights issue, which was fully underwritten by ABN AMRO Morgans and Wilson HTM (12/8) |
Pharmaxis |
Private placement and share purchase |
26.36S |
A$19.77 (US$15.1) |
Pharmaxis placed 22M shares with institutions and other investors at A75 cents per share; separately, it will issue about 4.36M shares under a share purchase plan (12/14) |
Physiomics |
Private placement of stock |
37.5S |
£0.75 (US$1.45) |
Physiomics sold the shares at 2 pence each, and with the deal began trading on the Alternative Investment Market (12/20) |
Prana |
Exercise of options |
9.5S |
A$4.75 (US$3.6) |
9.5M options that expired Dec. 1 were exercised for the purchase of one share at A$0.50 each (12/8) |
Provectus |
Private placement of stock and warrants |
0.557S and 0.835W |
$0.42 |
The shares were sold at $0.75 each and the warrants are exercisable at $1 per share; placement agent Venture Catalyst LLC received $41,762 in the deal (12/9) |
Resverlogix |
Bought-deal financing |
1.027S |
C$3.1 (US$2.55) |
The initial 2.64M shares in the deal were issued in November; the shares were purchased by First Associates Investments Inc. and its syndicate comprised Haywood Securities Inc., Loewen Ondaatje McCutcheon Ltd., Sprott Securities Inc. and Jennings Capital Inc. (12/16) |
| | ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | ||||
To read more on related topics, click on one of the words below.